EUA
AdviseDx SARS-CoV-2 IgM
FDA Emergency Use Authorization · Abbott Laboratories Inc. · Oct 1, 2021
Key facts
| Product | AdviseDx SARS-CoV-2 IgM |
|---|---|
| Company | Abbott Laboratories Inc. |
| Product type | IgM, CMIA |
| Date | Oct 1, 2021 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: